Form 4: Rhythm Pharmaceuticals Director Tetrault Trades Shares

Rhythm Pharmaceuticals Director Lynn A. Tetrault reported transactions involving common stock, restricted stock units, and stock options.

Summary

• Lynn A. Tetrault, a Director at Rhythm Pharmaceuticals, Inc., reported several transactions on June 23, 2026.
• These transactions include the acquisition of 4,712 shares of common stock, which were previously held as restricted stock units (RSUs).
• Additionally, Tetrault acquired 3,691 stock options with an exercise price of $107.55, expiring on June 23, 2036.
• Tetrault also acquired 2,324 RSUs.
• Following these transactions, Tetrault beneficially owns 11,712 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider equity transactions rather than significant financial results or strategic shifts.

Positives

• Director Lynn A. Tetrault acquired additional equity in the company through the vesting of restricted stock units and the grant of stock options.
• The acquisition of 4,712 shares from vested RSUs and 2,324 new RSUs indicates continued equity participation by a key insider.
• The grant of 3,691 stock options suggests potential future upside for the director tied to the company's stock performance.

Negatives

• The filing does not explicitly detail any negative financial performance or operational setbacks.

Risks

• The stock options granted have an exercise price of $107.55, implying that the company's stock price needs to exceed this level for the options to be profitable.
• The vesting of RSUs and stock options is subject to continued service, meaning any departure from the company could impact these holdings.

Future Outlook

The filing does not contain forward-looking statements or guidance. The details pertain to past transactions and the terms of equity awards.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The details of stock options and RSUs granted to Director Lynn A. Tetrault at Rhythm Pharmaceuticals are typical for executive compensation packages in the biotechnology and pharmaceutical sector, aiming to align insider interests with shareholder value.

Stakeholder Impact

• Shareholders: The transactions indicate continued commitment from a director, which can be viewed positively, but the exercise price of options suggests a need for significant stock price appreciation to realize value.

Next Steps

• The stock options granted will vest on or before June 24, 2027, subject to continued service.
• The newly acquired RSUs will vest on or before June 24, 2027, subject to continued service.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Lynn A. Tetrault, Director, Beneficial Ownership, SEC Filing